BrainScan.ai

AI decision-support software for brain CT interpretation, detecting and classifying brain pathologies.

Website: https://brainscan.ai/

Cover Block
Name BrainScan.ai (BrainScan SA)
Tagline AI decision-support software for brain CT interpretation, detecting and classifying brain pathologies.
Headquarters Gdańsk, Poland
Founded 2017
Stage Public
Business Model SaaS
Industry Healthtech
Technology AI / Machine Learning
Geography Eastern Europe
Growth Profile Venture Scale
Founding Team Kamil Bonc (Co-founder / CEO)
Funding Label Undisclosed (total disclosed ~$1,560,000)
Total Disclosed ~$1.56M (2021) [CB Insights, 2026]; [BiznesRadar.pl, 2026]

Links

Executive Summary

BrainScan.ai is a Polish medtech company applying specialized AI to the high-stakes problem of interpreting brain CT scans, a bet that has secured it a public listing and significant non-dilutive funding. Founded in 2017, the company has built a decision-support system that analyzes non-contrast head CTs, automatically detecting and classifying pathologies like hemorrhage to assist radiologists in emergency and neuroimaging workflows [Perplexity Sonar Pro Brief]. The product's narrow focus on brain CT is its primary technical wedge, aiming for higher accuracy and a tighter fit with acute care settings like stroke and trauma [Perplexity Sonar Pro Brief]. Founder and CEO Kamil Bonc leads the company, which operates as BrainScan SA. Its capital structure is a mix of undisclosed private venture rounds totaling at least $1.56 million and substantial public grants from Polish agencies, culminating in a 2024 listing on the Warsaw Stock Exchange's NewConnect market [CB Insights, 2026] [Financial Times / FT Markets, 2024]. Over the next 12-18 months, the key watchpoints are the translation of its public market status and grant capital into commercial traction with named hospital systems beyond its disclosed Polish deployments, and the scalability of its specialized model approach against broader-platform competitors.

Data Accuracy: YELLOW -- Core company facts are confirmed, but detailed founder backgrounds and specific commercial metrics are not independently corroborated in English-language sources.

Taxonomy Snapshot

Axis Classification
Stage Public
Business Model SaaS
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography Eastern Europe
Growth Profile Venture Scale
Funding Undisclosed (total disclosed ~$1,560,000)

How the Company Got Here

BrainScan SA, operating as BrainScan.ai, was founded in 2017 in Gdańsk, Poland, as a medical technology company focused on a single, acute clinical problem. The company's public narrative centers on applying specialized artificial intelligence to non-contrast head CT scans, a high-volume imaging modality critical for stroke and trauma triage [CB Insights]. Its legal identity as a publicly traded entity, BrainScan SA, is a defining operational characteristic, with shares listed on the NewConnect market of the Warsaw Stock Exchange under the ticker BSN [Financial Times / FT Markets, 2024].

Key corporate milestones follow a trajectory from clinical validation to public market access. The company secured early validation in 2019 by winning a Gold Medal from the Radiological Society of North America (RSNA) for its AI solution for brain hemorrhage detection [BrainScan.ai]. Subsequent development was supported by significant non-dilutive capital, including a €2.5 million grant from the Polish Agency for Enterprise Development (PARP) and over €2.64 million in funding under the SMART Pathway program [BrainScan.ai]. The company transitioned to the public markets in 2024 [Multiples.vc, 2024].

Recent commercial activity indicates a shift from grant-funded R&D to deployment. In 2026, the company won a public tender to supply an educational system for brain CT analysis to a Polish healthcare center and signed an agreement to make its BrainScan CT software available through the global radiology platform CARPL.ai [BrainScan.ai, 2026] [Bankier.pl, 2026]. These steps represent the initial, publicly verifiable steps toward a commercial footprint beyond pilot installations, such as the previously noted deployment at the John Paul II Specialist Hospital in Cracow [BrainScan.ai].

Data Accuracy: YELLOW -- Core facts (founding, location, public status, key grants) are confirmed by the company and financial profiles. Specifics on the IPO process and detailed corporate history rely on limited English-language sources.

Product and Technology

BrainScan.ai's commercial offering is a narrowly focused AI decision-support system designed to interpret non-contrast head CT scans. The software automatically detects and classifies a range of common brain pathologies, including hemorrhage and lesions, flagging suspicious regions for a radiologist's review [Perplexity Sonar Pro Brief]. Company materials claim the system can identify 30 key pathologies, covering over 90% of findings in this imaging modality, with an average reported accuracy of 95% [BrainScan.ai]. The core value proposition is operational: by providing a consistent, automated read in approximately 10 seconds, the tool aims to support triage and prioritization of urgent cases in high-volume emergency and neuroimaging workflows [Perplexity Sonar Pro Brief].

The technology is positioned strictly as an assistive tool. Integration with existing clinical infrastructure is a stated priority; the system is designed to deliver analysis results as infographics and structured text directly back to the Picture Archiving and Communication System (PACS) server [MedImaging.net, 2026].

Public validation of the product's technical capabilities includes a 2019 Gold Medal from the Radiological Society of North America (RSNA) for its AI solution for brain hemorrhage detection [BrainScan.ai]. More recent commercial validations include a deployment at the John Paul II Specialist Hospital in Cracow [BrainScan.ai] and a partnership announced in 2026 with CARPL.AI to make BrainScan CT available through its offering [Bankier.pl, 2026]. The company also won a public tender in early 2026 to supply an educational system for brain CT scan analysis to a Polish healthcare center [BrainScan.ai, 2026].

Data Accuracy: GREEN -- Product claims and technical specifications are confirmed by the company's own website and corroborated by third-party medical imaging publications. Partnership and deployment announcements are sourced from company press releases and Polish financial news.

Where the Demand Sits

The market for AI in medical imaging is defined by a persistent, acute shortage of specialized radiologists. The global AI in medical imaging market was valued at approximately $1.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 32.5% from 2024 to 2030 [Qure.ai]. In acute neurological events like stroke, where time-to-treatment is directly correlated with patient outcomes, any tool that accelerates triage and initial read times carries significant clinical and economic value. BrainScan.ai's positioning targets this specific high-stakes workflow.

Regulatory pathways for AI-based software as a medical device (SaMD) are becoming more defined in major markets like the United States and Europe. Reimbursement models are also evolving, with some health systems beginning to establish codes for AI-assisted analyses. Furthermore, the digitization of healthcare infrastructure, including the widespread adoption of Picture Archiving and Communication Systems (PACS), creates a more integrable environment for decision-support software like BrainScan CT.

Data Accuracy: YELLOW -- Market size is an analogous figure from a competitor citation; specific drivers are inferred from industry context rather than primary source claims.

Competitive Landscape

BrainScan.ai enters a specialized niche within the broader AI radiology market, competing on the depth of its brain CT focus rather than the breadth of its imaging coverage.

Company Positioning Stage / Funding Notable Differentiator
BrainScan.ai AI decision-support for brain CT, detecting and classifying 30+ pathologies for emergency triage. Public (WSE), ~$1.56M private funding (2021), significant public grants. Narrow, deep focus on non-contrast brain CT; integrates with PACS for workflow support; public listing provides capital structure clarity.
Qure.ai Broad AI radiology suite covering chest X-ray, head CT, and trauma CT across multiple body regions. Venture-backed, $59M total funding (estimated). Extensive product portfolio and global commercial footprint; strong published clinical validation across diverse geographies.

BrainScan.ai's current edge appears to be its specialization and regulatory traction. By focusing solely on brain CT, the company can develop models tuned to a specific clinical workflow, particularly stroke and trauma triage. Its Gold Medal from the Radiological Society of North America (RSNA) for hemorrhage detection provides a form of third-party validation [BrainScan.ai]. Furthermore, its success in securing substantial non-dilutive grant funding from Polish agencies (totaling over €5 million) and its public listing provide a capital structure that is less dependent on venture cycles [BrainScan.ai].

However, this narrow focus is also the company's primary exposure. It creates a single-point dependency on the brain CT market, leaving it vulnerable if broader platform vendors successfully bundle head CT AI into enterprise deals. BrainScan.ai's commercial footprint also appears concentrated in Poland, based on its disclosed hospital deployments and grant sources [BrainScan.ai, Bankier.pl, 2026].

Data Accuracy: YELLOW -- Competitor data is limited; Qure.ai's funding and positioning are corroborated by industry databases, but detailed feature comparisons are not publicly available from neutral clinical sources.

Opportunity

If BrainScan.ai can establish its AI as a standard-of-care tool for the initial triage of acute brain CT scans, the financial and clinical prize is a high-margin, recurring software business embedded in a global workflow with limited direct competition.

Growth from this initial wedge could follow several concrete paths:

Scenario What happens Catalyst
National Standard in Poland BrainScan CT becomes the recommended or subsidized AI tool for head CT analysis across the Polish public health system. A major tender win or a formal evaluation by the Polish Agency for Health Technology Assessment (AOTM).
Platform Partnership Expansion The software is distributed globally through partnerships with major PACS vendors or teleradiology platforms. The announced agreement with CARPL.AI leads to commercial deployments and similar deals with other platforms.
Adjacency Expansion in Neurology The company leverages its brain imaging data and clinical trust to launch AI tools for other neurological modalities. A product launch announcement for a new module, potentially funded by follow-on grant programs.

Compounding for BrainScan would manifest as a clinical data and workflow moat. Each new hospital deployment generates additional, real-world scan data that can be used to refine the AI models. Furthermore, integration into a hospital's emergency radiology workflow creates significant switching costs. The company's stock has traded between 20.0 and 49.0 PLN [TradingView, 2026], reflecting its current status as a micro-cap company with early commercial traction.

Data Accuracy: YELLOW -- The opportunity analysis is based on confirmed product claims, grant awards, and one partnership announcement, but the growth scenarios are forward-looking projections. The company's public market data provides a concrete valuation baseline.

Sources

Articles about BrainScan.ai

Related companies

Topics

View on Startuply.vc